Summary:
This study assessed the ability of recombinant human stem cell factor (rHuSCF) to mobilize stem cells in 44 patients who had failed a prior mobilization (CD34+ yield 0.5–1.9 × 106/kg BW) with filgrastim-alone or chemotherapy-plus-filgrastim. The same mobilization regimen was used with the addition of rHuSCF. In the filgrastim-alone group (n=13), rHuSCF 20 μg/kg was started 3 days before filgrastim and continued for the duration of filgrastim. In the chemotherapy-plus-filgrastim group (n=31), rHuSCF 20 μg/kg/day plus filgrastim 5–10 μg/kg/day were administered concurrently. Leukaphereses were continued to a maximum of four procedures or a target of ⩾3 × 106 CD34+ cells/kg. In both groups, CD34+ yield (× 106/kg BW) of the study mobilization was higher than that of the prior mobilization (median: 2.42 vs 0.84 P=0.002 and 1.64 vs 0.99 P=<0.001, respectively). In all 54 and 45% of patients in the filgrastim-alone group and chemotherapy-plus-filgrastim group, respectively, reached the threshold yield of 2 × 106/kg. The probability of a successful mobilization was the same in those with a CD34+ yield of 0.5–0.75 × 106/kg BW in the prior mobilization as in those with 0.76–1.99 × 106/kg BW. Downmodulation of c-kit expression and a lower percentage of Thy-1 positivity in the mobilized CD34+ cells were noted in the successful mobilizers compared with those in the poor mobilizers. This study shows that rhuSCF is effective in approximately half the patients who had failed a prior mobilization and allows them to proceed to transplant. It also points to the likely role of the SCF/c-kit ligand pair in mobilization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
To LB, Sheppard KM, Haylock DN et al. Single high dose of cyclophosphamide enable the collection of high numbers of haemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442–447.
Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filagrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339: 640–644.
Hoglund M, Smedmyr B, Simonsson B et al. Dose dependant mobilization of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 19–27.
To LB, Haylock DN, Simmons PJ, Juttner CA . The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–2258.
Broudy VC . Stem cell factor and hematopoiesis. Blood 1997; 90: 1345–1364.
Moskowitz CH, Stiff P, Gordon MS et al. Recombinant methionyl human stem factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkins lymphoma patients: results of a phase I/II trial. Blood 1997; 89: 3136–3147.
Begley CG, Basser R, Mansfield R et al. Enhanced levels and clonogenic capacity of blood progenitor cells following administration of SCF plus G-CSF to humans. Blood 1997; 90: 3378–3389.
Shpall EJ, Wheeler CA, Stewart A et al. A randomised phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491–2501.
Weaver A, Chang J, Wrigley E et al. Randomised comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998; 16: 2601–2612.
Basser RL, To LB, Begley G et al. Rapid haemopoeitic recovery after multiple high dose chemotherapy: enhancement of filgrastim-induced progenitor cell mobilization by recombinant human stem cell factor. J Clin Oncol 1998; 16: 1899–1908.
Stiff P, Gingrich R, Luger S et al. A randomised phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkins lymphoma. Bone Marrow Transplant 2000; 26: 471–481.
Lie AKW, Rawling TP, Bayly JL et al. Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of haemopoietic growth factor and chemotherapy. Br J Haematol 1996; 95: 39–44.
Lie AKW, Hui C-H, Rawling T et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 1998; 22: 853–857.
Roberts MM, Swart BW, Simmons PJ et al. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Br J Haematol 1999; 104: 778–784.
Simmons PJ, Leavesley DI, Levesque J-P et al. The mobilization of primitive haemopoietic progenitors into the peripheral blood. Stem Cells 1994; 12 (Suppl. 1): 187–202.
Ziegler BL, Valteri M, Porada GA et al. KDR receptor: a key marker defining haematopoietic stem cells. Science 1999; 285: 1553–1558.
Azar N, Vantelon JM, Hashmanti P et al. Ancestim(r-metHuSCF): mobilization of peripheral blood stem cells (PBSC) in patients with prior unsuccessful mobilization with G-CSF. Experience of 67 cases of compassionate use in France. Blood 2000; 96: 176a.
Ashman LK . The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31: 1037–1051.
To LB, Haylock DN, Dowse T et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994; 84: 2930–2939.
Yee Ns, Hsiau CW, Serve H et al. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J Biol Chem 1994; 269: 31991–31998.
Caruana G, Ashman LK, Fujita J, Gonda TJ . Responses of the murine myeloid cell line FDC-P1 to soluble and membrane-bound forms of steel factor (SLF). Exp Hematol 1993; 21: 761–768.
Dubois CM, Ruscetti FW, Stankova J, Keller JR . Transforming growth factor-beta 2 microglobulin regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. Blood 1994; 83: 3138–3145.
Cynshi O, Satoh K, Shimonaka Y et al. Reduced response to granulocyte colony-stimulating factor in W/W and SL/SL mice. Leukaemia 1991; 5: 75–80.
Kaneko Y, Takenawa J, Yoshida O et al. Adhesion of mouse mast cells to fibroblasts: adverse effects of steel (S1) mutation. J Cell Physiol 1991; 147: 224–230.
Avraham H, Scadden DT, Chi S et al. Interaction of human bone marrow fibroblasts with megakaryocytes: role of the c-kit ligand. Blood 1992; 80: 1679–1684.
Morrison SJ, Wright DE, Weissman IL . Cyclophosphamide/granulocyte colony-stimulating factor induces haematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA 1997; 94: 1908–1193.
Papayannopoulou T, Priestley GV, Nakamoto B . Anti VLA4/VCAM-1-induced mobilization requires cooperative signalling through the kit/mkit ligand pathway. Blood 1998; 91: 2231–2239.
Acknowledgements
We thank Diane Landorf for secretarial assistance, Melanie Seeger for literature searches, and Mary-Ann Foote for reviewing the manuscript. The following research nurses contributed to trial coordination and data collection: Marjorie Goward, Kerry Kristaly, Kathy Lape, Rosetta Maisano, Jenny Muirhead, Caroline Rawling, Leonie Snowden, and Sonya Stephens.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
To, L., Bashford, J., Durrant, S. et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 31, 371–378 (2003). https://doi.org/10.1038/sj.bmt.1703860
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703860
Keywords
This article is cited by
-
Turning Death to Growth: Hematopoietic Growth Factors Promote Neurite Outgrowth through MEK/ERK/p53 Pathway
Molecular Neurobiology (2018)
-
The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span
GeroScience (2018)
-
The combination of stem cell factor and granulocyte-colony stimulating factor for chronic stroke treatment in aged animals
Experimental & Translational Stroke Medicine (2012)
-
Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience
Bone Marrow Transplantation (2011)
-
Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
Bone Marrow Transplantation (2011)